title: Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline.
abstract: Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.
authors.affiliation: Albany Medical College, NY.
authors.forename: J C
authors.initials: JC
authors.lastname: Ruckdeschel
authors.forename: D
authors.initials: D
authors.lastname: Moores
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: L H
authors.initials: LH
authors.lastname: Einhorn
authors.forename: I
authors.initials: I
authors.lastname: Mandelbaum
authors.forename: J
authors.initials: J
authors.lastname: Koeller
authors.forename: G R
authors.initials: GR
authors.lastname: Weiss
authors.forename: M
authors.initials: M
authors.lastname: Losada
authors.forename: J H
authors.initials: JH
authors.lastname: Keller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D015505:Chest Tubes; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D015911:Sclerotherapy; D013752:Tetracycline / Q000008:administration & dosage* / Q000009:adverse effects; D013907:Thoracostomy / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D013752:Tetracycline